Do You Lose Muscle Mass on Wegovy — and Does It Matter?

Does semaglutide itself cause muscle loss, or is it just the calorie deficit?

This is the right question, and the honest answer is: mostly the calorie deficit. When the body loses weight at any meaningful pace, it draws on both fat stores and lean tissue, including muscle. That is a basic physiological reality that applies whether you are dieting conventionally, using a GLP-1 medicine, or recovering from illness. Wegovy works partly by reducing appetite quite substantially, which creates a calorie gap, and that gap is what drives the lean mass change, not semaglutide acting directly on muscle fibres.

Body composition data from the STEP 1 trial, published in the New England Journal of Medicine, showed that participants lost on average around 15% of their body weight over 68 weeks. Lean mass did fall, but fat mass fell substantially more in proportional and absolute terms. The split was roughly 75–80% fat mass to 20–25% lean mass across different analyses, depending on the measurement method used. So the vast majority of weight coming off was fat. That does not make the lean mass loss irrelevant, but it reframes it.

The ongoing REMODEL trial is looking specifically at muscle and body composition outcomes in people with obesity taking semaglutide, and its data will sharpen what clinicians can say with confidence. For now, the best framing is that semaglutide accelerates a calorie deficit, and the muscle implications are driven by that deficit, not by the drug class itself.

Does Wegovy make you lose more muscle than other weight-loss approaches?

Not necessarily. This is where the comparison matters. Studies looking at body composition across different weight-loss methods (low-calorie diets, bariatric surgery, and GLP-1 medicines) consistently find that the lean mass proportion lost is broadly similar when the rate and scale of weight loss are comparable. Losing weight quickly and in large amounts carries more lean mass risk than losing it slowly, regardless of the method.

One pattern worth noting: because Wegovy can produce quite substantial weight loss over a relatively compressed period, the total volume of lean mass lost may be larger in absolute grams than someone who loses the same percentage weight over twice the time. The rate matters, and that is another reason protein adequacy and resistance training are discussed seriously in clinical guidance, not just as wellness advice.

There is a separate and genuinely uncertain question about whether GLP-1 medicines might, over time, have any direct effects on muscle biology through the GI and metabolic pathways they affect. Research is active. For now, NHS guidance on semaglutide does not identify muscle wasting as a documented side effect, and clinicians generally treat the muscle question as a nutrition and activity management issue rather than a pharmacological one.

If you want to understand how tirzepatide compares from a body composition perspective, our page on the effect of semaglutide on muscle mass goes into more detail on the mechanism side.

What actually helps preserve muscle while losing weight on Wegovy?

Two things have the most evidence behind them: adequate protein intake and resistance exercise. Neither is novel advice, but both matter more when appetite is suppressed and total calorie intake drops.

Protein is the main structural input for muscle repair and maintenance. When you are eating significantly less, hitting a protein target takes deliberate effort, it does not happen by accident if your appetite is low and your meals are smaller. Most clinical guidance suggests aiming for at least 1.2g of protein per kilogram of body weight per day during active weight loss, though the right figure for any individual is something to discuss with a dietitian or prescriber. Practical tip: if you take your tablet first thing in the morning and wait the required 30 minutes before eating, use that window to think about what your first protein source of the day will be rather than defaulting to whatever is easiest.

Resistance training (weight-bearing exercise that challenges the muscles) signals the body to hold onto lean tissue even during a deficit. Cardiovascular activity is good for overall health but does relatively little to preserve muscle specifically. Even two sessions a week of structured resistance work makes a measurable difference in body composition studies. Our page on how to protect muscle on Wegovy covers this in practical terms.

The broader context of weight management on a GLP-1 medicine includes lifestyle changes alongside the medicine itself, which is reflected in how Wegovy is licensed: alongside a reduced-calorie diet and increased physical activity. That framing is not incidental, it is where most of the muscle-preservation benefit sits.

Should concerns about muscle stop someone from using Wegovy?

For most people with obesity or overweight and a weight-related health condition, the answer is no, but the concern deserves a proper clinical conversation, not dismissal. Excess body fat carries its own risks to metabolic health, cardiovascular function and joint load. The question is not whether any muscle loss is acceptable in isolation; it is whether the overall health balance of treatment is favourable for this person at this point.

There are specific groups where the muscle question warrants extra clinical attention: older adults, where muscle mass is already declining with age; people with existing musculoskeletal conditions; and anyone with a history of low muscle mass or frailty. In those cases, a prescriber may factor body composition into how treatment is monitored. Our detailed page on Wegovy and muscle mass covers the older adult picture specifically.

For a broader understanding of how semaglutide works as a treatment, the Wegovy overview is a good starting point. And if you have a specific concern about muscle loss that you would like a clinician to weigh up as part of your assessment, that is exactly what a consultation with our prescribers is designed for. nume prescribes after individual clinical review, a real prescriber reads your answers, not a system.

Pricing context, if that is relevant to your decision, is on our Wegovy prices page.